Mereo BioPharma Group (Mereo BioPharma Group) Equity-to-Asset

: 0.76 (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Mereo BioPharma Group's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $50.54 Mil. Mereo BioPharma Group's Total Assets for the quarter that ended in Dec. 2023 was $66.50 Mil. Therefore, Mereo BioPharma Group's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.76.

The historical rank and industry rank for Mereo BioPharma Group's Equity-to-Asset or its related term are showing as below:

MREO' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.24 Med: 0.66 Max: 0.91
Current: 0.76

During the past 9 years, the highest Equity to Asset Ratio of Mereo BioPharma Group was 0.91. The lowest was -0.24. And the median was 0.66.

MREO's Equity-to-Asset is ranked better than
61.33% of 1567 companies
in the Biotechnology industry
Industry Median: 0.67 vs MREO: 0.76

Mereo BioPharma Group Equity-to-Asset Historical Data

The historical data trend for Mereo BioPharma Group's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mereo BioPharma Group Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Equity-to-Asset

0.47

-0.24

0.70

0.66

0.76

Mereo BioPharma Group Semi-Annual Data
	Jun15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Equity-to-Asset													0.70	0.64	0.66	0.72	0.76

Competitive Comparison

For the Biotechnology subindustry, Mereo BioPharma Group's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mereo BioPharma Group Equity-to-Asset Distribution

For the Biotechnology industry and Healthcare sector, Mereo BioPharma Group's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Mereo BioPharma Group's Equity-to-Asset falls into.

Mereo BioPharma Group Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Mereo BioPharma Group's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	50.537	/	66.499
	=	0.76

Mereo BioPharma Group's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	50.537	/	66.499
	=	0.76

Mereo BioPharma Group (NAS:MREO) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Mereo BioPharma Group Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Mereo BioPharma Group's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Mereo BioPharma Group (Mereo BioPharma Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mereo BioPharma Group PLC (NAS:MREO) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

MAH0:Germany MAH0:Germany

Address

One Cavendish Place, 4th Floor, London, GBR, W1G 0QF

Website

https://www.mereobiopharma.com

Mereo BioPharma Group PLC is a multi-asset, clinical-stage biopharmaceutical company. It is focused on the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. Its oncology product candidate is etigilimab, for patients with solid tumors. Some of the other products in the pipeline are setrusumab, alvelestat, leflutrozole, navicixizumab, and acumapimod.